Treatment of rheumatoid arthritis with higher dose intravenous methotrexate

S. Gabriel; E. Creagan; W. M. O'Fallon; J. Jaquith; T. W. Bunch

Treatment of rheumatoid arthritis with higher dose intravenous methotrexate

S. Gabriel, E. Creagan, W. M. O'Fallon, J. Jaquith, T. W. Bunch

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m²; final dose, 26 mg/m²), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.

Original language	English (US)
Pages (from-to)	460-465
Number of pages	6
Journal	Journal of Rheumatology
Volume	17
Issue number	4
State	Published - 1990

Keywords

methotrexate
rheumatoid arthritis
treatment

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Cite this

@article{12ba880f012e420d819888b5700801a1,

title = "Treatment of rheumatoid arthritis with higher dose intravenous methotrexate",

abstract = "A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.",

keywords = "methotrexate, rheumatoid arthritis, treatment",

author = "S. Gabriel and E. Creagan and O'Fallon, {W. M.} and J. Jaquith and Bunch, {T. W.}",

year = "1990",

language = "English (US)",

volume = "17",

pages = "460--465",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "4",

}

TY - JOUR

T1 - Treatment of rheumatoid arthritis with higher dose intravenous methotrexate

AU - Gabriel, S.

AU - Creagan, E.

AU - O'Fallon, W. M.

AU - Jaquith, J.

AU - Bunch, T. W.

PY - 1990

Y1 - 1990

N2 - A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.

AB - A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.

KW - methotrexate

KW - rheumatoid arthritis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=0025329610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025329610&partnerID=8YFLogxK

M3 - Article

C2 - 2348423

AN - SCOPUS:0025329610

SN - 0315-162X

VL - 17

SP - 460

EP - 465

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 4

ER -

Treatment of rheumatoid arthritis with higher dose intravenous methotrexate

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this